Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer Le-chen LiGuo-dong LiuYan-bo Li Review Article 04 December 2013 Pages: 439 - 449
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study J. Casal RubioJ. L. Fírvida-PérezS. Vázquez Original Article 19 December 2013 Pages: 451 - 457
Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs Jie ZhongWenxue MaoYueming Ma Original Article 22 December 2013 Pages: 459 - 466
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies Daruka MahadevanGregory Ryan SuttonRazelle Kurzrock Original Article 04 January 2014 Pages: 467 - 473
Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry Ella S. M. NgS. Bill KangarlooAnthony M. Magliocco Original Article Open access 12 January 2014 Pages: 475 - 484
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies Justine Yang BruceJill M. KolesarGlenn Liu Original Article 12 January 2014 Pages: 485 - 493
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers Jennifer J. WhelerFilip JankuRazelle Kurzrock Original Article 17 January 2014 Pages: 495 - 501
Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients Paola MillaChiara FioritoPaolo Gontero Original Article 18 January 2014 Pages: 503 - 509
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors Hiroshi WakuiNoboru YamamotoTomohide Tamura Original Article Open access 18 January 2014 Pages: 511 - 516
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old Milena GusellaAntonio BononiFelice Pasini Original Article 18 January 2014 Pages: 517 - 524
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer Pasquale CironeCatharine J. AndresenCedo M. Bagi Original Article 19 January 2014 Pages: 525 - 538
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors Edward SausvillePatricia LoRussoAdrian Senderowicz Original Article 22 January 2014 Pages: 539 - 549
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians Lei ChengMing LiXiao-Ping Qian Original Article 22 January 2014 Pages: 551 - 560
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors Clinton F. StewartMichael TagenLinda M. Smiley Original Article 22 January 2014 Pages: 561 - 568
shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells Hongjian YangYue LuZhiqiang Ling Original Article 22 January 2014 Pages: 569 - 576
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers Kaku SaitoHirotaka NagashimaShigeru Takagi Original Article 23 January 2014 Pages: 577 - 583
High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate Bradley S. HanberryRyan BergerJason A. Zastre Original Article 23 January 2014 Pages: 585 - 594
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors E. Gabriela ChioreanChristopher SweeneyRobert Amato Original Article 23 January 2014 Pages: 595 - 604
Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels Joji KitayamaShigenobu EmotoToshiaki Watanabe Original Article 25 January 2014 Pages: 605 - 612
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects Marta HamiltonJulie L. WolfBert L. Lum Original Article 29 January 2014 Pages: 613 - 621
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors H. MurakamiT. KurataS. Kuroda Original Article Open access 30 January 2014 Pages: 623 - 630
Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer Faruk TasSenem KarabulutDerya Duranyildiz Original Article 30 January 2014 Pages: 631 - 637
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma Raymond YungVahid SeyfoddinLai-Ming Ching Original Article 30 January 2014 Pages: 639 - 649
CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity K. E. BurnsM. A. GoldthorpeN. A. Helsby Short Communication 12 February 2014 Pages: 651 - 655
